SFM
CRVS icon

Sphera Funds Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Sphera Funds Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.66M Sell
244,961
-3,000
-1% -$41.6K 0.48% 72
2026
Q1 		$3.63M Sell
247,961
-159,748
-39% -$2.55M 0.58% 60
2025
Q4 		$3.14M Hold
407,709
– – 0.61% 60
2025
Q3 		$3M Buy
407,709
+224,615
+123% +$1.15M 0.63% 53
2025
Q2 		$732K Sell
183,094
-22,765
-11% -$82.8K 0.17% 94
2025
Q1 		$655K Sell
205,859
-294,632
-59% -$1.39M 0.15% 99
2024
Q4 		$2.68M Buy
+500,491
New +$3.74M 0.48% 67
2019
Q2 		– Sell
-83,607
Closed -$336K – 95
2019
Q1 		$336K Sell
83,607
-237,823
-74% -$1M 0.03% 101
2018
Q4 		$1.18M Hold
321,430
– – 0.13% 88
2018
Q3 		$2.76M Sell
321,430
-14,557
-4% -$146K 0.32% 78
2018
Q2 		$3.69M Buy
335,987
+14,557
+5% +$162K 0.51% 59
2018
Q1 		$3.71M Buy
321,430
+100,000
+45% +$946K 0.56% 52
2017
Q4 		$2.29M Hold
221,430
– – 0.27% 84
2017
Q3 		$3.53M Sell
221,430
-36,235
-14% -$501K 0.5% 55
2017
Q2 		$3.12M Sell
257,665
-21,501
-8% -$230K 0.53% 55
2017
Q1 		$5.8M Sell
279,166
-41,063
-13% -$643K 1.13% 21
2016
Q4 		$4.58M Sell
320,229
-4,824
-1% -$73.4K 1.16% 20
2016
Q3 		$5.35M Hold
325,053
– – 0.87% 25
2016
Q2 		$4.58M Buy
325,053
+214,132
+193% +$2.89M 1.19% 22
2016
Q1 		$1.61M Buy
+110,921
New +$1.59M 0.35% 66

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Sphera Funds Management's CRVS Position: Q2 2026 in Review

Sphera Funds Management reduced its Corvus Pharmaceuticals (CRVS) stake by 1.2% in Q2 2026, selling an estimated $41.6K and leaving 244,961 shares worth $3.66M. The position accounts for 0.48% of the portfolio, ranked #72.

Sphera Funds Management first reported a position in CRVS in Q1 2016 and has held it in 20 quarters since. The position peaked at $5.8M in Q1 2017. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Sphera Funds Management held 244,961 shares of Corvus Pharmaceuticals worth $3.66M as of Q2 2026.
  • Sphera Funds Management sold 3,000 Corvus Pharmaceuticals shares in Q2 2026, an estimated $41.6K.
  • Corvus Pharmaceuticals made up 0.48% of Sphera Funds Management's portfolio in Q2 2026, its #72 holding.
  • Sphera Funds Management first reported a position in Corvus Pharmaceuticals in Q1 2016 and has held it in 20 quarters since.
  • Sphera Funds Management's Corvus Pharmaceuticals position peaked at $5.8M in Q1 2017.
  • 174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Sphera Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.